To test this hypothesis, CD8+ T lymphocytes were depleted in vivo by the intraperitoneal administration of an anti-CD8 antibody, starting from one day prior to tumor cell injection until day 17 [22,23] (Figure 4A). The gene discussed is CD8A; the disease is neoplasm.